Antioxidants in the treatment of chronic liver diseases: why is the efficacy evidence so weak in humans?
Lu
Shelly C
SC
Division of Gastroenterology and Liver Diseases, University of Southern California Research Center for Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. shellylu@usc.edu
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D000529:Complementary Therapies / Q000639:trends; D005419:Flavonoids / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D008107:Liver Diseases / Q000188:drug therapy* / Q000503:physiopathology; D010636:Phenols / Q000627:therapeutic use; D059808:Polyphenols; D017382:Reactive Oxygen Species / Q000378:metabolism; D015203:Reproducibility of Results; D013662:Tea; D016896:Treatment Outcome; D014801:Vitamin A / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D000975:Antioxidants; D005419:Flavonoids; D010636:Phenols; D059808:Polyphenols; D017382:Reactive Oxygen Species; D013662:Tea; D014801:Vitamin A; D014810:Vitamin E; D001205:Ascorbic Acid